Heparin Market Projections 2026 | Sanofi, Hepalink group, Pfizer, Leo Pharma, and Laboratories Farmaceuticos Rovi SA

Global heparin industry trends will be prominently driven by the inclining demand for anticoagulant products that are used to treat venous thromboembolism and coronary artery ailments. The Center for Disease Control and Prevention (CDC), revealed that over 18.2 million adults were diagnosed with coronary artery diseases in 2017 were aged above 20 years.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/4837

This factor is likely to stir the adoption of anticoagulant in the coming years. Furthermore, several initiatives and programs have been formulated by the National Institutes of Health (NIH) and CDC to mount the awareness related to the prevention of thrombosis-associated complications in the initial stages across the U.S. As per reports, the global heparin market size will surpass an annual estimation of close to USD 6.6 billion by 2026.

Low molecular weight heparin segment recorded more than USD 3.6 billion in global revenue in 2019, slated for an exponential growth rate through the coming years. This is owing to the rise in heparin use in surgeries as well as in the treatment of coagulation diseases. Researchers experimenting at the Rensselaer Polytechnic Institute and the University of North Carolina (UNC) have come up with a synthetic, low molecular weight heparin structure that is safe to use. These synthetic products can be reversed during an activity using protamine besides being cost-effective compared to the heparin compounds derived from animals.

Porcine sourced heparin segment contributed to over 98.8% of the overall share in 2019 as it extensively helps in the prevention of blood clots post-surgery, in dialysis and blood transfusion as well as during the collection of the blood samples. The demand can be further attributed to the higher adoption of the porcine based product in patients affected with atrial fibrillation.

Application of heparin in coronary artery diseases was valued at USD 1 billion in 2019 and is pegged to rise over the coming years owing to the consistent prevalence of the disorder in emerging countries. Recurring cases of arterial thrombosis that are caused by damaged arteries may lead to a rise in myocardial infarction and coronary artery issues. This trend is likely to influence the demand for heparin doses.

Heparin anticoagulants witness high distribution across the online, hospital, and retail pharmacies. Online pharmacies offer significant discount rates and access to an extensive range of products along with doorstep delivery, subsequently attracting a larger consumer base. There is a growing popularity among the young and millennial population for online shopping across the developing nations.

The revenue collected from online segment was annually pegged at 14.7% of the global market share in 2019. The novel coronavirus pandemic could also have influenced the product distribution through pharmacies in recent months.

Asia Pacific heparin industry share will gain significant traction through 2026 due to the prominent presence of local manufacturers across the southeast region, besides the existence of a large patient population in India and China that is vulnerable to chronic ailments. As per reports, venous thromboembolism (VTE) emerged as among the most common ailments affecting Asians in 2017, while the incidence rate of the disorder yearly valued at nearly 100 for every 100,000 in the total population.

Request for customization @ https://www.gminsights.com/roc/4837

Heparin suppliers across the globe are keen on implementing various strategies like acquisitions, launches, and business mergers along with compliance with regulatory policies for the development of the novel products to increase their global presence.

For instance, Amphastar Pharmaceuticals in 2018 launched a new drug application supplement for producing a semi-purified heparin at its subsidiary location. The product also received approval from the U.S. FDA in the same year. Sanofi, Laboratorios Farmaceuticos Rovi SA, Leo Pharma Hepalink group, and Pfizer are a few of the other firms in the sector.

Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com

About Global Market Insights, Inc.
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.

This release was published on openPR.